Evidence map›Paper›PMID 31889140›Full record

ReviewNature reviews. Endocrinology2020

New insights into the pathogenesis and nonsurgical management of Graves orbitopathy.

Peter N Taylor, Lei Zhang, Richard W J Lee, Ilaria Muller, Daniel G Ezra, Colin M Dayan, George J Kahaly, Marian Ludgate

Abstract readReview
PubMed Publisher
In one paragraph

Review in Nature reviews. Endocrinology, 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 167 papers, 9 of them syntheses that pooled it.

0numbers the graph read from it
0cells of the map it votes in
167citing papers in PubMed, 9 pooled it
18.6field-weighted citation impact, top 1% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

167 citing papers in PubMed, 9 syntheses or guidelines pooled it, 299 citations in OpenAlex.

  1. Pooled it
  2. Pooled it
  3. Pooled it
  4. Pooled it
  5. Pooled it
  6. Pooled it
  7. Pooled it
  8. Pooled it
  9. Pooled it
  10. Trial
  11. Trial
  12. Trial
  13. Using 24-h intraocular pressure-related patterns to identify open-angle glaucoma in thyroid eye disease.Graefe's archive for clinical and experimental ophthalmology = Albrecht von Graefes Archiv fur klinische und experimentelle Ophthalmologie · 2023
    Trial
  14. Trial
  15. Article
  16. Article
  17. IntegratedEuropean journal of nuclear medicine and molecular imaging · 2026
    Article
  18. Article
  19. Article
  20. Review

107 more citing papers are in PubMed but not listed here.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

8 authors at 4 institutions in 3 countries.

Peter N Taylor *Thyroid Research Group, Systems Immunity Research Institute, Cardiff University School of Medicine, Cardiff, UK. taylorpn@cardiff.ac.uk.
Lei Zhang *Thyroid Research Group, Systems Immunity Research Institute, Cardiff University School of Medicine, Cardiff, UK.
Richard W J LeeMoorfields Eye Hospital NHS Foundation Trust, London, UK.
Ilaria MullerThyroid Research Group, Systems Immunity Research Institute, Cardiff University School of Medicine, Cardiff, UK.ORCID http://orcid.org/0000-0003-2926-0722
Daniel G EzraMoorfields Eye Hospital NHS Foundation Trust, London, UK.
Colin M DayanThyroid Research Group, Systems Immunity Research Institute, Cardiff University School of Medicine, Cardiff, UK.
George J Kahaly *Department of Medicine I, Johannes Gutenberg University Medical Center, Mainz, Germany.
Marian Ludgate *Thyroid Research Group, Systems Immunity Research Institute, Cardiff University School of Medicine, Cardiff, UK.
Cardiff University · GBMoorfields Eye Hospital NHS Foundation Trust · GBFondazione IRCCS Ca' Granda Ospedale Maggiore Policlinico · ITJohannes Gutenberg University Mainz · DE

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Graves orbitopathy, also known as thyroid eye disease or thyroid-associated orbitopathy, is visually disabling, cosmetically disfiguring and has a substantial negative impact on a patient's quality of life. There is increasing awareness of the need for early diagnosis and rapid specialist input from endocrinologists and ophthalmologists. Glucocorticoids are the mainstay of treatment; however, recurrence occurs frequently once these are withdrawn. Furthermore, in >60% of cases, normal orbital anatomy is not restored, and skilled rehabilitative surgery is required. Clinical trials have shown that considerable benefit can be derived from the addition of antiproliferative agents (such as mycophenolate or azathioprine) in preventing deterioration after steroid cessation. In addition, targeted biologic therapies have shown promise, including teprotumumab, which reduces proptosis, rituximab (anti-CD20), which reduces inflammation, and tocilizumab, which potentially benefits both of these parameters. Other strategies such as orbital radiotherapy have had their widespread role in combination therapy called into question. The pathophysiology of Graves orbitopathy has also been revised with identification of new potential therapeutic targets. In this Review we provide an up-to-date overview of the field, outline the optimal management of Graves orbitopathy and summarize the research developments in this area to highlight future research questions and direct future clinical trials.

Indexed as

Disease ManagementAntibodies, Monoclonal, HumanizedClinical Trials as TopicDrug Therapy, CombinationGlucocorticoidsGraves OphthalmopathyHumansAntibodies, Monoclonal, HumanizedGlucocorticoidsteprotumumabtocilizumab

Identifiers

PMID31889140
OpenAlexW2998265514

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.